Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.51 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3150232 | 0.84 | CYP2A6 (0.59) | CYP19A1TBXAS1CYP2A6OPRM1OPRK1 | |
| SCHEMBL30287240 | 0.84 | CYP2A6 (0.59) | CYP19A1TBXAS1CYP2A6OPRM1OPRK1 | |
| SCHEMBL13873185 | 0.81 | CYP19A1 (0.46) | CYP19A1TBXAS1CYP2A6OPRM1OPRK1 | |
| SCHEMBL3791450 | 0.81 | CYP19A1 (0.51) | CYP19A1TBXAS1CYP2A6OPRM1OPRK1 | |
| SCHEMBL20562508 | 0.81 | CYP19A1 (0.51) | CYP19A1TBXAS1CYP2A6OPRM1OPRK1 | |
| SCHEMBL47979 | 0.81 | CYP19A1 (0.43) | CYP19A1TBXAS1CYP2A6OPRM1OPRK1 | |
| SCHEMBL3796692 | 0.78 | CYP19A1 (0.49) | CYP19A1TBXAS1OPRM1OPRK1 | |
| SCHEMBL3623024 | 0.78 | CYP19A1 (0.49) | CYP19A1TBXAS1CYP2A6OPRM1OPRK1 | |
| SCHEMBL10768021 | 0.77 | CYP19A1 (0.48) | CYP19A1TBXAS1OPRM1OPRK1 | |
| SCHEMBL10664242 | 0.77 | CYP19A1 (0.48) | CYP19A1TBXAS1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160008322-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP (CA) | 2016-01-14 | — | — | US | disclosed |
| US-20140314685-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2014-10-23 | — | — | US | disclosed |
| US-20130171077-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2013-07-04 | — | — | US | disclosed |
| US-RE43676-E1 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-RE43676-E1 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-RE43676-E1 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| EP-1614419-B1 | PREVENTIVE/REMEDY FOR RETINAL NERVE DISEASES CONTAINING ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2012-08-08 | — | — | EP | disclosed |
| CN-101643470-B | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO LTD | 2012-08-01 | — | — | CN | disclosed |
| US-8129535-B2 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-03-06 | — | — | US | disclosed |
| US-8129535-B2 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20050020481-A1 | Ion channel modulating compounds and uses thereof | BAIN ALLAN I (CA) | 2005-01-27 | — | — | US | disclosed |
| CN-1571786-A | Alkyl ether derivative or salt thereof | TOYAMA CHEMICAL CO LTD (JP) | 2005-01-26 | — | — | CN | disclosed |
| US-6797726-B1 | N-alkoxyalkyl-N,N-dialkylamine derivatives or salts thereof, and remedies for nerve degeneration diseases containing the same | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-09-28 | — | — | US | disclosed |
| EP-1437353-A1 | ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-07-14 | — | — | EP | disclosed |
| EP-1422217-A2 | Aminocyclohexyl ether compounds and uses thereof | Cardiome Pharma Corp. (CA) | 2004-05-26 | — | — | EP | disclosed |
| EP-1087934-B1 | AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF | NORTRAN PHARMACEUTICALS INC (CA) | 2004-02-25 | — | — | EP | disclosed |
| EP-1186594-A1 | N-ALKOXYALKYL-N,N-DIALKYLAMINE DERIVATIVES OR SALTS THEREOF, AND REMEDIES FOR NERVE DEGENERATION DISEASES CONTAINING THE SAME | TOYAMA CHEMICAL CO., LTD. (JP) | 2002-03-13 | — | — | EP | disclosed |
| CN-1303364-A | Aminocyclohexyl ether compounds and uses thereof | NORTRAN PHARMACEUTICALS INC (CA) | 2001-07-11 | — | — | CN | disclosed |
| EP-1087934-A1 | AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF | Nortran Pharmaceuticals Inc. (CA) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999050225-A1 | AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF | NORTRAN PHARMACEUTICALS INC. (CA) | 1999-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130171077-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | TRPV1, TRPA1, KCNN2 | CYP19A1 3139/4885TBXAS1 606/4885CYP2A6 1521/4885 |
| US-20050020481-A1 | Ion channel modulating compounds and uses thereof | TRPV1, TRPA1, KCNN2 | CYP19A1 3139/4885TBXAS1 606/4885CYP2A6 1521/4885 |
| US-20160008322-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | TRPV1, TRPA1, KCNN2 | CYP19A1 3139/4885TBXAS1 606/4885CYP2A6 1521/4885 |
| US-20140314685-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | TRPV1, TRPA1, KCNN2 | CYP19A1 3139/4885TBXAS1 606/4885CYP2A6 1521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.